1gij › Citations

Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.

Ikuta M, Kamata K, Fukasawa K, Honma T, Machida T, Hirai H, Suzuki-Takahashi I, Hayama T, Nishimura S
J Biol Chem 276 27548-54 (2001)
Related entries: 1gih, 1gii

Cited: 44 times
EuropePMC logo PMID: 11335721

Abstract

Genetic alteration of one or more components of the p16(INK4A)-CDK4,6/cyclin D-retinoblastoma pathway is found in more than half of all human cancers. Therefore, CDK4 is an attractive target for the development of a novel anticancer agent. However, it is difficult to make CDK4-specific inhibitors that do not possess activity for other kinases, especially CDK2, because the CDK family has high structural homology. The three-dimensional structure of CDK2, particularly that bound with the inhibitor, has provided useful information for the synthesis of CDK2-specific inhibitors. The same approach used to make CDK4-specific inhibitors was hindered by the failure to obtain a crystal structure of CDK4. To overcome this problem, we synthesized a CDK4 mimic CDK2 protein in which the ATP binding pocket of CDK2 was replaced with that of CDK4. This CDK4 mimic CDK2 was crystallized both in the free and inhibitor-bound form. The structural information thus obtained was found to be useful for synthesis of a CDK4-specific inhibitor that does not have substantial CDK2 activity. Namely, the data suggest that CDK4 has additional space that will accommodate a large substituent such as the CDK4 selective inhibitor. Inhibitors designed to bind into this large cavity should be selective for CDK4 without having substantial CDK2 activity. This design principle was confirmed in the x-ray crystal structure of the CDK4 mimic CDK2 with a new CDK4 selective inhibitor bound.

Articles - 1gij mentioned but not cited (6)

  1. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug. Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. PLoS One 10 e0132072 (2015)
  2. Structural and functional restraints on the occurrence of single amino acid variations in human proteins. Gong S, Blundell TL. PLoS One 5 e9186 (2010)
  3. Prediction of calcium-binding sites by combining loop-modeling with machine learning. Liu T, Altman RB. BMC Struct Biol 9 72 (2009)
  4. Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining. Verma N, Rai AK, Kaushik V, Brünnert D, Chahar KR, Pandey J, Goyal P. Sci Rep 6 33949 (2016)
  5. Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation. Zhang W, Roy Burman SS, Chen J, Donovan KA, Cao Y, Shu C, Zhang B, Zeng Z, Gu S, Zhang Y, Li D, Fischer ES, Tokheim C, Shirley Liu X. Genomics Proteomics Bioinformatics 20 882-898 (2022)
  6. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. Li Z, Ishida R, Liu Y, Wang J, Li Y, Gao Y, Jiang J, Che J, Sheltzer JM, Robers MB, Zhang T, Westover KD, Nabet B, Gray NS. Eur J Med Chem 238 114433 (2022)


Reviews citing this publication (7)

  1. Structural biology in drug design: selective protein kinase inhibitors. Scapin G. Drug Discov Today 7 601-611 (2002)
  2. Selectivity and potency of cyclin-dependent kinase inhibitors. Sridhar J, Akula N, Pattabiraman N. AAPS J 8 E204-21 (2006)
  3. Pharmacological targeting of CDK9 in cardiac hypertrophy. Krystof V, Chamrád I, Jorda R, Kohoutek J. Med Res Rev 30 646-666 (2010)
  4. Recent advances in de novo design strategy for practical lead identification. Honma T. Med Res Rev 23 606-632 (2003)
  5. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Waters NC, Geyer JA. Expert Opin Ther Targets 7 7-17 (2003)
  6. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Nat Rev Urol 19 305-320 (2022)
  7. Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives. Ardevines S, Marqués-López E, Herrera RP. Curr Med Chem 30 1145-1174 (2023)

Articles citing this publication (31)

  1. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Mol Pharmacol 80 565-572 (2011)
  2. The crystal structure of human CDK7 and its protein recognition properties. Lolli G, Lowe ED, Brown NR, Johnson LN. Structure 12 2067-2079 (2004)
  3. High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Koresawa M, Okabe T. Assay Drug Dev Technol 2 153-160 (2004)
  4. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. Am J Pathol 161 405-411 (2002)
  5. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. Davies TG, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CC, McHardy T, Collins I, Garrett MD, Workman P, Woodhead SJ, Jhoti H, Barford D. J Mol Biol 367 882-894 (2007)
  6. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, Wang S, Zheleva DI, Marriage H, Lane DP, Taylor P, Fischer PM, Walkinshaw MD. Structure 11 399-410 (2003)
  7. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Holton S, Merckx A, Burgess D, Doerig C, Noble M, Endicott J. Structure 11 1329-1337 (2003)
  8. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Anderson M, Beattie JF, Breault GA, Breed J, Byth KF, Culshaw JD, Ellston RP, Green S, Minshull CA, Norman RA, Pauptit RA, Stanway J, Thomas AP, Jewsbury PJ. Bioorg Med Chem Lett 13 3021-3026 (2003)
  9. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines. Beattie JF, Breault GA, Ellston RP, Green S, Jewsbury PJ, Midgley CJ, Naven RT, Minshull CA, Pauptit RA, Tucker JA, Pease JE. Bioorg Med Chem Lett 13 2955-2960 (2003)
  10. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM. Chem Biol 11 525-534 (2004)
  11. Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. Terasawa K, Yoshimatsu K, Iemura S, Natsume T, Tanaka K, Minami Y. Mol Cell Biol 26 3378-3389 (2006)
  12. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach. Tripathi SK, Singh SK, Singh P, Chellaperumal P, Reddy KK, Selvaraj C. J Mol Recognit 25 504-512 (2012)
  13. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Moshinsky DJ, Bellamacina CR, Boisvert DC, Huang P, Hui T, Jancarik J, Kim SH, Rice AG. Biochem Biophys Res Commun 310 1026-1031 (2003)
  14. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Kawanishi N, Sugimoto T, Shibata J, Nakamura K, Masutani K, Ikuta M, Hirai H. Bioorg Med Chem Lett 16 5122-5126 (2006)
  15. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Park H, Yeom MS, Lee S. Chembiochem 5 1662-1672 (2004)
  16. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Breault GA, Ellston RP, Green S, James SR, Jewsbury PJ, Midgley CJ, Pauptit RA, Minshull CA, Tucker JA, Pease JE. Bioorg Med Chem Lett 13 2961-2966 (2003)
  17. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors. Al-Warhi T, El Kerdawy AM, Aljaeed N, Ismael OE, Ayyad RR, Eldehna WM, Abdel-Aziz HA, Al-Ansary GH. Molecules 25 E2031 (2020)
  18. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Chohan TA, Chen JJ, Qian HY, Pan YL, Chen JZ. Mol Biosyst 12 1250-1268 (2016)
  19. Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma. Wang B, Peng F, Huang W, Zhou J, Zhang N, Sheng J, Haruehanroengra P, He G, Han B. Acta Pharm Sin B 10 1492-1510 (2020)
  20. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD, Brizuela L, Brenner SL, Stouten PF. J Comput Aided Mol Des 19 111-122 (2005)
  21. kinDOCK: a tool for comparative docking of protein kinase ligands. Martin L, Catherinot V, Labesse G. Nucleic Acids Res 34 W325-9 (2006)
  22. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. Hazel P, Kroll SH, Bondke A, Barbazanges M, Patel H, Fuchter MJ, Coombes RC, Ali S, Barrett AG, Freemont PS. ChemMedChem 12 372-380 (2017)
  23. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Persson T, Yde CW, Rasmussen JE, Rasmussen TL, Guerra B, Issinger OG, Nielsen J. Org Biomol Chem 5 3963-3970 (2007)
  24. INH14, a Small-Molecule Urea Derivative, Inhibits the IKKα/β-Dependent TLR Inflammatory Response. Drexel M, Kirchmair J, Santos-Sierra S. Chembiochem 20 710-717 (2019)
  25. Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2. Kelly MD, Mancera RL. ChemMedChem 1 366-375 (2006)
  26. Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors. Lu Y, Knapp M, Crawford K, Warne R, Elling R, Yan K, Doyle M, Pardee G, Zhang L, Ma S, Mamo M, Ornelas E, Pan Y, Bussiere D, Jansen J, Zaror I, Lai A, Barsanti P, Sim J. J Mol Biol 429 1684-1704 (2017)
  27. Virtual screening studies reveal linarin as a potential natural inhibitor targeting CDK4 in retinoblastoma. Sivashanmugam M, Raghunath C, Vetrivel U. J Pharmacol Pharmacother 4 256-264 (2013)
  28. Comparison of the Inhibitory Binding Modes Between the Planar Fascaplysin and Its Nonplanar Tetrahydro-β-carboline Analogs in CDK4. Liang Y, Quan H, Bu T, Li X, Liu X, Wang S, He D, Jia Q, Zhang Y. Front Chem 9 614154 (2021)
  29. Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies. Zeifman AA, Stroylov VS, Novikov FN, Stroganov OV, Zakharenko AL, Khodyreva SN, Lavrik OI, Chilov GG. J Mol Model 18 2553-2566 (2012)
  30. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking. Zheng J, Kong H, Wilson JM, Guo J, Chang Y, Yang M, Xiao G, Sun P. PLoS One 9 e93704 (2014)
  31. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313. Talapati SR, Nataraj V, Pothuganti M, Gore S, Ramachandra M, Antony T, More SS, Krishnamurthy NR. Acta Crystallogr F Struct Biol Commun 76 350-356 (2020)


Quick links